ImmunityBio, Inc. - Common Stock (NQ:IBRX)

6.090 +0.145 (+2.44%)

Streaming Delayed Price Updated: 10:28 AM EST, Feb 17, 2026 Add to My Watchlist

Price and Volume

Volume	5,885,233
Open	6.260
Bid (Size)	6.080 (1,200)
Ask (Size)	6.090 (1,100)
Prev. Close	5.945
Today's Range	5.930 - 6.280
52wk Range	1.830 - 8.280
Shares Outstanding	391,156,513
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’ ↗

Today 8:48 EST

The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks.

Via Stocktwits

ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

Today 6:07 EST

From ImmunityBio, Inc.

Via Business Wire

Performance

YTD	+201.5%	+201.5%
1 Month	-6.0%	-6.0%
3 Month	+200.0%	+200.0%
6 Month	+150.6%	+150.6%
1 Year	+81.8%	+81.8%

More News

Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗

Today 3:31 EST

Via Stocktwits

Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs ↗

February 02, 2026

Via Stocktwits

IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing ↗

January 20, 2026

Via Stocktwits

Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals ↗

Today 0:31 EST

Via Stocktwits

IBRX Stokes Retail Chatter — Investors See Anktiva Beat Merck’s Keytruda With Approval In EU ↗

February 13, 2026

Via Stocktwits

ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC)

February 10, 2026

Via AB Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

February 03, 2026

From Pomerantz LLP

Via GlobeNewswire

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

February 02, 2026

From ImmunityBio

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

January 27, 2026

From Pomerantz LLP

Via GlobeNewswire

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer ↗

January 26, 2026

Via The Motley Fool

IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research ↗

January 26, 2026

Via Stocktwits

Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗

January 26, 2026

Via Stocktwits

$5 Stocks: NDRA, IBRX, MOVE, RVLY Drawing Attention Watch Now!

January 25, 2026

Via AB Newswire

Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month ↗

January 23, 2026

Via The Motley Fool

IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz ↗

January 23, 2026

Via Stocktwits

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

January 23, 2026

From ImmunityBio, Inc.

Via Business Wire

Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗

January 21, 2026

Via The Motley Fool

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer ↗

January 20, 2026

Via The Motley Fool

Which stocks are most active on Tuesday? ↗

January 20, 2026

Via Chartmill

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

January 20, 2026

From ImmunityBio, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Slide As Trump Ramps Up Greenland Threats: Why NFLX, CRML, TSLA, VERO, SRXH Are On Traders' Radar Today ↗

January 20, 2026

Via Stocktwits

Why Is ImmunityBio Stock Back In Retail Spotlight Today? ↗

January 19, 2026

Via Stocktwits

Nasdaq, S&P 500 Futures Slide On Greenland Tensions: Why NVDA, MU, IBRX, CRML And VERO Are On Traders’ Radar Today ↗

January 19, 2026

Via Stocktwits

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?

Yes, ImmunityBio, Inc. - Common Stock is publicly traded.

What exchange does ImmunityBio, Inc. - Common Stock trade on?

ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ImmunityBio, Inc. - Common Stock?

The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market

What is the current price of ImmunityBio, Inc. - Common Stock?

The current price of ImmunityBio, Inc. - Common Stock is 6.090

When was ImmunityBio, Inc. - Common Stock last traded?

The last trade of ImmunityBio, Inc. - Common Stock was at 02/17/26 10:28 AM ET

What is the market capitalization of ImmunityBio, Inc. - Common Stock?

The market capitalization of ImmunityBio, Inc. - Common Stock is 2.38B

How many shares of ImmunityBio, Inc. - Common Stock are outstanding?

ImmunityBio, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.